Partnered with HK Federation of Insurers to Share Non-invasive Early Cancer Detection Technology
Supported by the Hong Kong Federation of Insurers (“HKFI”), an industry sharing themed “Screening for Early Cancers by Circulating DNA Analysis”, was successfully held on 17 September 2021. The online seminar attracted more than 180 senior managements from 37 insurance companies and led to heated discussions.
The seminar invited the respected professor in the pathology field from the Chinese University of Hong Kong as keynote speaker, to introduce how the pioneering Next-generation Sequencing technology help with early cancer detection. During the talk, the professor explained the development progress of this state-of-the-art technology and discussed how insurance companies and their products could create synergies together when incorporated with the technology, with an aim to safeguard the population’s health.
HKFI was established on 8 August 1988 to advance and promote the development of the insurance business in Hong Kong. Fully recognised by the HKSAR government, HKFI is the representative body of the insurance industry. Some of its member companies include AXA, Manulife, Prudential, HSBC Insurance, AIA, China Taiping Insurance and other leading insurance companies in the world and Asia-Pacific region.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
